Tumor type M2 pyruvate kinase expression in advanced breast cancer

Anticancer Research

Volumn 20, Issue 6 D, 2000, Pages 5077-5082

  Luftner D ^a   Mesterharm, J ^a   Akrivakis, C ^a   Geppert, R ^a   Petrides, P E ^a   Wernecke, K D ^a   Possinger, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Breast cancer; CA27.29; Predictive tumor markers; Tu M2 PK; Tumor M2 pyruvate kinase isoenzyme

Indexed keywords

ANTHRACYCLINE; CA 15-3 ANTIGEN; CA 27-29 ANTIGEN; GEMCITABINE; ISOENZYME; PYRUVATE KINASE; PYRUVATE KINASE M2; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHEMOLUMINESCENCE; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PYRUVATE KINASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0034451402     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Tumour marker CA15-3: Possible uses in the routine management of breast cancer
2. Performance characteristics of the ACSTM BR: aA comparison with three other assays that also measure CA15-3
3. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers
4. Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer
5. Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells
6. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas
7. Die Bedeutung der Pyruvatkinase in der Onkologie
8. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells
9. Quantitative determination (ELISA) of pyruvate kinase type tumor M2 - A new tumor marker
10. Value of the serum levels of the tumor marker Tu M2-PK in pancreatic cancer
11. L-and M2-pyruvate kinase expression in renal cell carcinomas and their metastases
12. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma
13. Tu M2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions
14. Studies on associations of glycolytic and glutaminolytic enzymes in MCF-7 cells: Role of P36
15. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?
16. Quantitative detection of tumor M2-PK in serum and plasma
17. Comparison of standard and CA12-5 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel